한글목차

최근 작은 간섭 리보핵산(siRNA) 시장 규모는 비약적으로 확대되고 있습니다. 2025년 188억 6,000만 달러에서 2026년에는 226억 9,000만 달러에 이르고, CAGR 20.3%의 성장이 전망되고 있습니다. 지난 몇 년간의 성장은 분자생물학 연구의 발전, 유전성 질환 및 만성질환 증가, RNA 기반 치료제의 초기 단계의 성공, 유전체학 분야의 연구 자금 증가, RNA 간섭 메커니즘의 확립 등에 기인하는 것으로 보입니다.

작은 간섭 리보핵산(siRNA) 시장 규모는 향후 몇 년간 급성장이 전망됩니다. 2030년에는 470억 7,000만 달러에 이르고, CAGR은 20.0%를 나타낼 전망입니다. 예측 기간 동안의 성장 요인으로는 RNA 치료에 대한 규제 당국의 승인 증가, 개인 맞춤형 의료에 대한 수요 증가, 나노 입자 전달 기술의 혁신, 제약 기업의 투자 증가, 감염성 질환 및 희귀질환에 대한 작은 간섭 리보핵산(siRNA)의 적용 확대 등을 꼽을 수 있습니다. 주요 동향으로는 RNA 간섭 치료의 임상 도입 증가, 표적 유전자 침묵화 기법에 대한 관심 증가, 첨단 작은 간섭 리보핵산(siRNA) 전달 플랫폼의 확대, 정밀 치료 개발에 대한 투자 증가, 확장 가능한 RNA 제조에 대한 중점 강화 등이 예측됩니다.

개인 맞춤형 의료에 대한 수요 증가는 향후 몇 년 동안 소형 간섭성 리보핵산(RNA) 시장의 성장을 견인할 것으로 예측됩니다. 맞춤의료는 치료 결과의 향상과 케어의 개선을 목적으로 환자의 유전적 요인, 환경적 요인, 생활습관에 따라 치료법을 맞춤화하는 의료 전략입니다. 유전체 기술의 발전으로 유전적 변이의 정확한 규명과 환자 맞춤형 치료법 개발이 가능해짐에 따라 개인 맞춤형 의료에 대한 수요가 증가하고 있습니다. 작은 간섭 리보핵산(작은 간섭 리보핵산(siRNA))은 정밀한 유전자 침묵을 가능하게 함으로써 개인 맞춤형 의료를 지원하고, 특정 유전성 질환 및 질병 치료에 효과를 발휘합니다. 질병을 유발하는 mRNA를 선택적으로 억제하여 오프타겟 효과를 최소화하여 치료 효과와 환자 예후를 개선합니다. 예를 들어, 미국 비영리단체인 맞춤형 의료연합(PMC)에 따르면, 2024년 2월 현재 미국 식품의약국(FDA)은 2023년 26건의 새로운 맞춤형 의료 제품을 승인했습니다. 이는 2022년 12건에서 증가한 수치입니다. 그 결과, 개인 맞춤형 의료에 대한 수요가 증가하면서 소분자 간섭 리보핵산(작은 간섭 리보핵산(siRNA)) 시장 확대가 촉진되고 있습니다.

작은 간섭 리보핵산(siRNA)(small interfering ribonucleic acid) 치료제 시장에서 사업을 전개하고 있는 주요 기업들은 희귀 유전질환 치료를 위한 혁신적인 기전의 규제 승인 획득에 집중하고 있으며, 환자들에게 지속적인 효과를 제공하고 투여 빈도를 최소화하는 것을 목표로 하고 있습니다. 규제 승인은 의약품이나 치료법을 안전하게 시험, 판매, 환자에게 투여할 수 있도록 허가하는 당국의 공식적인 승인을 의미합니다. 예를 들어, 2025년 3월 미국 바이오 제약기업인 알니람 파마슈티컬스(Aruniram Pharmaceuticals)는 미국 식품의약국(FDA)으로부터 Qfitlia(피츠실란)의 승인을 획득했습니다. 이는 억제제 유무에 관계없이 12세 이상의 성인 및 청소년 A형 또는 B형 혈우병 환자를 대상으로 하는 최초의 작은 간섭 리보핵산(siRNA) 기반 치료제입니다. 이 치료법은 항트롬빈 농도를 낮추어 트롬빈 생성을 촉진하고, 응고 형성을 도와 출혈 에피소드를 감소시키도록 설계되었습니다. Qfitlia는 피하주사로 2개월에 한 번씩 투여할 수 있어 혈우병 관리에 있어 새로운 비인자 치료 옵션을 제공합니다.

목차

제1장 주요 요약

제2장 시장 특징

제3장 시장 공급망 분석

제4장 세계 시장 동향과 전략

제5장 최종 이용 산업 시장 분석

제6장 시장 : 금리, 인플레이션, 지정학, 무역 전쟁과 관세의 영향, 관세 전쟁과 무역 보호주의의 공급망에 대한 영향, 코로나 팬데믹이 시장에 미치는 영향을 포함한 거시경제 시나리오

제7장 세계 전략 분석 프레임워크, 현재 시장 규모, 시장 비교 및 성장률 분석

제8장 TAM(Total Addressable Market) 규모

제9장 시장 세분화

제10장 지역별/국가별 분석

제11장 아시아태평양 시장

제12장 중국 시장

제13장 인도 시장

제14장 일본 시장

제15장 호주 시장

제16장 인도네시아 시장

제17장 한국 시장

제18장 대만 시장

제19장 동남아시아 시장

제20장 서유럽 시장

제21장 영국 시장

제22장 독일 시장

제23장 프랑스 시장

제24장 이탈리아 시장

제25장 스페인 시장

제26장 동유럽 시장

제27장 러시아 시장

제28장 북미 시장

제29장 미국 시장

제30장 캐나다 시장

제31장 남미 시장

제32장 브라질 시장

제33장 중동 시장

제34장 아프리카 시장

제35장 시장 규제 상황과 투자환경

제36장 경쟁 구도와 기업 개요

제37장 기타 주요 기업 및 혁신 기업

제38장 세계 시장 경쟁 벤치마킹과 대시보드

제39장 주요 인수합병(M&A)

제40장 시장 잠재력이 높은 국가, 부문, 전략

제41장 부록

영문목차

Small interfering ribonucleic acid (RNA) is a short, double-stranded RNA molecule that is crucial for gene silencing through a mechanism known as RNA interference (RNAi). It attaches to complementary messenger RNA (mRNA) sequences, resulting in their degradation and blocking protein production. The main function of siRNA is to control or reduce the expression of specific genes and is often utilized in research and therapeutic settings to target genes that cause diseases.

The main types of small interfering ribonucleic acid (RNA) include liposome-based systemic therapy and nanoparticle-based systemic therapy. Liposome-based systemic therapy is a drug delivery method that utilizes liposomes to carry therapeutic agents throughout the body via the bloodstream. These therapies are applied for various conditions, including cardiovascular diseases, respiratory diseases, oncology, neurodegenerative diseases, and infectious diseases, and serve end users such as hospitals, research institutions, pharmaceutical and biotechnology companies, and academic institutions.

Tariffs are impacting the small interfering ribonucleic acid market by increasing costs of imported nucleotides, lipid nanoparticles, specialized reagents, laboratory instruments, and advanced manufacturing equipment required for siRNA synthesis and delivery. Research institutions and pharmaceutical companies in North America and Europe are most affected due to dependence on imported high-purity raw materials, while Asia-Pacific faces cost pressures on export-oriented production. These tariffs are raising development and production costs and extending clinical timelines. However, they are also encouraging local sourcing of reagents, domestic manufacturing of RNA components, and regional expansion of biopharmaceutical production capabilities.

The small interfering ribonucleic acid (rna) market research report is one of a series of new reports from The Business Research Company that provides small interfering ribonucleic acid (rna) market statistics, including small interfering ribonucleic acid (rna) industry global market size, regional shares, competitors with a small interfering ribonucleic acid (rna) market share, detailed small interfering ribonucleic acid (rna) market segments, market trends and opportunities, and any further data you may need to thrive in the small interfering ribonucleic acid (rna) industry. This small interfering ribonucleic acid (rna) market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The small interfering ribonucleic acid (rna) market size has grown exponentially in recent years. It will grow from $18.86 billion in 2025 to $22.69 billion in 2026 at a compound annual growth rate (CAGR) of 20.3%. The growth in the historic period can be attributed to advancements in molecular biology research, rising prevalence of genetic and chronic diseases, early success of rna-based therapeutics, increased research funding in genomics, establishment of rna interference mechanisms.

The small interfering ribonucleic acid (rna) market size is expected to see exponential growth in the next few years. It will grow to $47.07 billion in 2030 at a compound annual growth rate (CAGR) of 20.0%. The growth in the forecast period can be attributed to increasing regulatory approvals for rna therapies, growing demand for personalized medicine, expansion of nanoparticle delivery innovations, rising investments by pharmaceutical companies, broader application of sirna in infectious and rare diseases. Major trends in the forecast period include increasing clinical adoption of rna interference therapies, growing focus on targeted gene silencing approaches, expansion of advanced sirna delivery platforms, rising investment in precision therapeutics development, enhanced emphasis on scalable rna manufacturing.

The increasing demand for personalized medicine is anticipated to drive the growth of the small interfering ribonucleic acid (RNA) market in the coming years. Personalized medicine is a medical strategy that customizes treatments for individual patients based on their genetic, environmental, and lifestyle factors to enhance outcomes and improve care. The demand for personalized medicine is rising due to advances in genomic technologies, which allow for the accurate identification of genetic variations and the development of tailored treatments for patients. Small interfering ribonucleic acid (siRNA) supports personalized medicine by enabling precise gene silencing, making it effective for treating specific genetic disorders and diseases. It minimizes off-target effects by selectively inhibiting disease-causing mRNA, thereby improving therapeutic efficacy and patient outcomes. For example, in February 2024, according to the Personalized Medicine Coalition (PMC), a US-based nonprofit organization, the U.S. Food and Drug Administration (FDA) approved 26 new personalized medicines in 2023, up from 12 approvals in 2022. Consequently, the growing demand for personalized medicine is fueling the expansion of the small interfering ribonucleic acid (RNA) market.

Major companies operating in the small interfering ribonucleic acid (siRNA) therapeutics market are concentrating on obtaining regulatory approvals for innovative mechanisms to treat rare genetic disorders, aiming to provide long-lasting effects and minimize dosing frequency for patients. Regulatory approvals are official authorizations from authorities permitting a drug or therapy to be safely tested, marketed, or administered to patients. For example, in March 2025, Alnylam Pharmaceuticals Inc., a US-based biopharmaceutical company, received approval from the U.S. Food and Drug Administration (FDA) for Qfitlia (fitusiran), the first small interfering ribonucleic acid (siRNA)-based therapy for adults and adolescents aged 12 years and older with hemophilia A or B, with or without inhibitors. The therapy is designed to reduce antithrombin levels, thereby increasing thrombin generation to support clot formation and decrease bleeding episodes. Qfitlia provides a subcutaneous, once-every-two-month dosing schedule, offering a novel, non-factor therapeutic option for hemophilia management.

In May 2025, AbbVie Inc., a US-based biopharmaceutical company, formed a partnership with ADARx Pharmaceuticals Inc. Through this collaboration, AbbVie Inc. aims to combine ADARx Pharmaceuticals Inc.'s proprietary RNA technology with its scientific expertise to develop next-generation small interfering RNA (siRNA) therapies, advancing progress in neuroscience, immunology, and oncology. ADARx Pharmaceuticals Inc. is a biotechnology company focused on developing small interfering ribonucleic acid (siRNA)-based therapies that target specific mRNA to treat diseases.

Major companies operating in the small interfering ribonucleic acid (rna) market are Novartis AG, Thermo Fisher Scientific Inc., GlaxoSmithKline plc, Sanofi S.A., Sarepta Therapeutics Inc., Alnylam Pharmaceuticals Inc., Ionis Pharmaceuticals Inc., Wave Life Sciences Ltd., Silence Therapeutics plc, Arrowhead Pharmaceuticals Inc., Quark Pharmaceuticals Inc., Arbutus Biopharma Corporation, Evox Therapeutics Ltd., Phio Pharmaceuticals Inc., Genecon Biotechnologies Co. Ltd., Olix Pharmaceuticals Inc., Benitec Biopharma Ltd., Bio-Path Holdings Inc., Calando Pharmaceuticals Inc., Sirnaomics Ltd.

North America was the largest region in the small interfering ribonucleic acid (RNA) market in 2025. The regions covered in the small interfering ribonucleic acid (rna) market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the small interfering ribonucleic acid (rna) market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The small interfering ribonucleic acid (RNA) market consists of revenues earned by entities by providing services such as gene silencing assays, delivery system development, molecular diagnostics, preclinical testing, and laboratory research support. The market value includes the value of related goods sold by the service provider or included within the service offering. The small interfering ribonucleic acid (RNA) market also includes sales of synthesis kits, lipid nanoparticles, delivery vectors, RNAi assay kits, transfection reagents, and RNA extraction kits. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Small Interfering Ribonucleic Acid (RNA) Market Global Report 2026 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses small interfering ribonucleic acid (rna) market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 16 geographies.
• Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, inflation and interest rate fluctuations, and evolving regulatory landscapes.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on end user analysis.
• Benchmark performance against key competitors based on market share, innovation, and brand strength.
• Evaluate the total addressable market (TAM) and market attractiveness scoring to measure market potential.
• Suitable for supporting your internal and external presentations with reliable high-quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for small interfering ribonucleic acid (rna) ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The small interfering ribonucleic acid (rna) market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market. This section also examines key products and services offered in the market, evaluates brand-level differentiation, compares product features, and highlights major innovation and product development trends.
• The supply chain analysis section provides an overview of the entire value chain, including key raw materials, resources, and supplier analysis. It also provides a list competitor at each level of the supply chain.
• The updated trends and strategies section analyses the shape of the market as it evolves and highlights emerging technology trends such as digital transformation, automation, sustainability initiatives, and AI-driven innovation. It suggests how companies can leverage these advancements to strengthen their market position and achieve competitive differentiation.
• The regulatory and investment landscape section provides an overview of the key regulatory frameworks, regularity bodies, associations, and government policies influencing the market. It also examines major investment flows, incentives, and funding trends shaping industry growth and innovation.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
• The total addressable market (TAM) analysis section defines and estimates the market potential compares it with the current market size, and provides strategic insights and growth opportunities based on this evaluation.
• The market attractiveness scoring section evaluates the market based on a quantitative scoring framework that considers growth potential, competitive dynamics, strategic fit, and risk profile. It also provides interpretive insights and strategic implications for decision-makers.
• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
• Expanded geographical coverage includes Taiwan and Southeast Asia, reflecting recent supply chain realignments and manufacturing shifts in the region. This section analyzes how these markets are becoming increasingly important hubs in the global value chain.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The company scoring matrix section evaluates and ranks leading companies based on a multi-parameter framework that includes market share or revenues, product innovation, and brand recognition.

Scope

• Markets Covered:1) By Type: Liposome Systemic Therapy; Nanoparticle-Based Systemic Therapy
• 2) By Indication: Cardiovascular Diseases; Respiratory Diseases; Oncology; Neurodegenerative Diseases; Infectious Diseases
• 3) By End-User: Hospital; Research Institutions; Pharmaceutical And Biotechnology Companies; Academic Institutions
• Subsegments:
• 1) By Liposome Systemic Therapy: Cationic Liposome Delivery; Neutral Liposome Delivery; Pegylated Liposome Delivery; Targeted Liposome Delivery
• 2) By Nanoparticle-Based Systemic Therapy: Lipid Nanoparticle Delivery; Polymer Nanoparticle Delivery; Gold Nanoparticle Delivery; Silica Nanoparticle Delivery
• Companies Mentioned: Novartis AG; Thermo Fisher Scientific Inc.; GlaxoSmithKline plc; Sanofi S.A.; Sarepta Therapeutics Inc.; Alnylam Pharmaceuticals Inc.; Ionis Pharmaceuticals Inc.; Wave Life Sciences Ltd.; Silence Therapeutics plc; Arrowhead Pharmaceuticals Inc.; Quark Pharmaceuticals Inc.; Arbutus Biopharma Corporation; Evox Therapeutics Ltd.; Phio Pharmaceuticals Inc.; Genecon Biotechnologies Co. Ltd.; Olix Pharmaceuticals Inc.; Benitec Biopharma Ltd.; Bio-Path Holdings Inc.; Calando Pharmaceuticals Inc.; Sirnaomics Ltd.
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Taiwan; Russia; South Korea; UK; USA; Canada; Italy; Spain.
• Regions: Asia-Pacific; South East Asia; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time Series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data Segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery Format: Word, PDF or Interactive Report
• + Excel Dashboard
• Added Benefits
• Bi-Annual Data Update
• Customisation
• Expert Consultant Support

Added Benefits available all on all list-price licence purchases, to be claimed at time of purchase. Customisations within report scope and limited to 20% of content and consultant support time limited to 8 hours.

Table of Contents

1. Executive Summary

• 1.1. Key Market Insights (2020-2035)
• 1.2. Visual Dashboard: Market Size, Growth Rate, Hotspots
• 1.3. Major Factors Driving the Market
• 1.4. Top Three Trends Shaping the Market

2. Small Interfering Ribonucleic Acid (RNA) Market Characteristics

• 2.1. Market Definition & Scope
• 2.2. Market Segmentations
• 2.3. Overview of Key Products and Services
• 2.4. Global Small Interfering Ribonucleic Acid (RNA) Market Attractiveness Scoring And Analysis
  • 2.4.1. Overview of Market Attractiveness Framework
  • 2.4.2. Quantitative Scoring Methodology
  • 2.4.3. Factor-Wise Evaluation
• Growth Potential Analysis, Competitive Dynamics Assessment, Strategic Fit Assessment And Risk Profile Evaluation
• 2.4.4. Market Attractiveness Scoring and Interpretation
• 2.4.5. Strategic Implications and Recommendations

3. Small Interfering Ribonucleic Acid (RNA) Market Supply Chain Analysis

• 3.1. Overview of the Supply Chain and Ecosystem
• 3.2. List Of Key Raw Materials, Resources & Suppliers
• 3.3. List Of Major Distributors and Channel Partners
• 3.4. List Of Major End Users

4. Global Small Interfering Ribonucleic Acid (RNA) Market Trends And Strategies

• 4.1. Key Technologies & Future Trends
  • 4.1.1 Biotechnology, Genomics & Precision Medicine
  • 4.1.2 Artificial Intelligence & Autonomous Intelligence
  • 4.1.3 Industry 4.0 & Intelligent Manufacturing
  • 4.1.4 Digitalization, Cloud, Big Data & Cybersecurity
  • 4.1.5 Sustainability, Climate Tech & Circular Economy
• 4.2. Major Trends
  • 4.2.1 Increasing Clinical Adoption Of RNA Interference Therapies
  • 4.2.2 Growing Focus On Targeted Gene Silencing Approaches
  • 4.2.3 Expansion Of Advanced siRNA Delivery Platforms
  • 4.2.4 Rising Investment In Precision Therapeutics Development
  • 4.2.5 Enhanced Emphasis On Scalable RNA Manufacturing

5. Small Interfering Ribonucleic Acid (RNA) Market Analysis Of End Use Industries

• 5.1 Hospitals
• 5.2 Research Institutions
• 5.3 Pharmaceutical Companies
• 5.4 Biotechnology Companies
• 5.5 Academic Institutions

6. Small Interfering Ribonucleic Acid (RNA) Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, Supply Chain Impact from Tariff War & Trade Protectionism, And Covid And Recovery On The Market

7. Global Small Interfering Ribonucleic Acid (RNA) Strategic Analysis Framework, Current Market Size, Market Comparisons And Growth Rate Analysis

• 7.1. Global Small Interfering Ribonucleic Acid (RNA) PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 7.2. Global Small Interfering Ribonucleic Acid (RNA) Market Size, Comparisons And Growth Rate Analysis
• 7.3. Global Small Interfering Ribonucleic Acid (RNA) Historic Market Size and Growth, 2020 - 2025, Value ($ Billion)
• 7.4. Global Small Interfering Ribonucleic Acid (RNA) Forecast Market Size and Growth, 2025 - 2030, 2035F, Value ($ Billion)

8. Global Small Interfering Ribonucleic Acid (RNA) Total Addressable Market (TAM) Analysis for the Market

• 8.1. Definition and Scope of Total Addressable Market (TAM)
• 8.2. Methodology and Assumptions
• 8.3. Global Total Addressable Market (TAM) Estimation
• 8.4. TAM vs. Current Market Size Analysis
• 8.5. Strategic Insights and Growth Opportunities from TAM Analysis

9. Small Interfering Ribonucleic Acid (RNA) Market Segmentation

• 9.1. Global Small Interfering Ribonucleic Acid (RNA) Market, Segmentation By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Liposome Systemic Therapy, Nanoparticle-Based Systemic Therapy
• 9.2. Global Small Interfering Ribonucleic Acid (RNA) Market, Segmentation By Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Cardiovascular Diseases, Respiratory Diseases, Oncology, Neurodegenerative Diseases, Infectious Diseases
• 9.3. Global Small Interfering Ribonucleic Acid (RNA) Market, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Hospital, Research Institutions, Pharmaceutical And Biotechnology Companies, Academic Institutions
• 9.4. Global Small Interfering Ribonucleic Acid (RNA) Market, Sub-Segmentation Of Liposome Systemic Therapy, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Cationic Liposome Delivery, Neutral Liposome Delivery, Pegylated Liposome Delivery, Targeted Liposome Delivery
• 9.5. Global Small Interfering Ribonucleic Acid (RNA) Market, Sub-Segmentation Of Nanoparticle-Based Systemic Therapy, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Lipid Nanoparticle Delivery, Polymer Nanoparticle Delivery, Gold Nanoparticle Delivery, Silica Nanoparticle Delivery

10. Small Interfering Ribonucleic Acid (RNA) Market Regional And Country Analysis

• 10.1. Global Small Interfering Ribonucleic Acid (RNA) Market, Split By Region, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• 10.2. Global Small Interfering Ribonucleic Acid (RNA) Market, Split By Country, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

11. Asia-Pacific Small Interfering Ribonucleic Acid (RNA) Market

• 11.1. Asia-Pacific Small Interfering Ribonucleic Acid (RNA) Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 11.2. Asia-Pacific Small Interfering Ribonucleic Acid (RNA) Market, Segmentation By Type, Segmentation By Indication, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

12. China Small Interfering Ribonucleic Acid (RNA) Market

• 12.1. China Small Interfering Ribonucleic Acid (RNA) Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 12.2. China Small Interfering Ribonucleic Acid (RNA) Market, Segmentation By Type, Segmentation By Indication, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

13. India Small Interfering Ribonucleic Acid (RNA) Market

• 13.1. India Small Interfering Ribonucleic Acid (RNA) Market, Segmentation By Type, Segmentation By Indication, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

14. Japan Small Interfering Ribonucleic Acid (RNA) Market

• 14.1. Japan Small Interfering Ribonucleic Acid (RNA) Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 14.2. Japan Small Interfering Ribonucleic Acid (RNA) Market, Segmentation By Type, Segmentation By Indication, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

15. Australia Small Interfering Ribonucleic Acid (RNA) Market

• 15.1. Australia Small Interfering Ribonucleic Acid (RNA) Market, Segmentation By Type, Segmentation By Indication, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

16. Indonesia Small Interfering Ribonucleic Acid (RNA) Market

• 16.1. Indonesia Small Interfering Ribonucleic Acid (RNA) Market, Segmentation By Type, Segmentation By Indication, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

17. South Korea Small Interfering Ribonucleic Acid (RNA) Market

• 17.1. South Korea Small Interfering Ribonucleic Acid (RNA) Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 17.2. South Korea Small Interfering Ribonucleic Acid (RNA) Market, Segmentation By Type, Segmentation By Indication, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

18. Taiwan Small Interfering Ribonucleic Acid (RNA) Market

• 18.1. Taiwan Small Interfering Ribonucleic Acid (RNA) Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 18.2. Taiwan Small Interfering Ribonucleic Acid (RNA) Market, Segmentation By Type, Segmentation By Indication, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

19. South East Asia Small Interfering Ribonucleic Acid (RNA) Market

• 19.1. South East Asia Small Interfering Ribonucleic Acid (RNA) Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 19.2. South East Asia Small Interfering Ribonucleic Acid (RNA) Market, Segmentation By Type, Segmentation By Indication, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

20. Western Europe Small Interfering Ribonucleic Acid (RNA) Market

• 20.1. Western Europe Small Interfering Ribonucleic Acid (RNA) Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 20.2. Western Europe Small Interfering Ribonucleic Acid (RNA) Market, Segmentation By Type, Segmentation By Indication, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

21. UK Small Interfering Ribonucleic Acid (RNA) Market

• 21.1. UK Small Interfering Ribonucleic Acid (RNA) Market, Segmentation By Type, Segmentation By Indication, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

22. Germany Small Interfering Ribonucleic Acid (RNA) Market

• 22.1. Germany Small Interfering Ribonucleic Acid (RNA) Market, Segmentation By Type, Segmentation By Indication, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

23. France Small Interfering Ribonucleic Acid (RNA) Market

• 23.1. France Small Interfering Ribonucleic Acid (RNA) Market, Segmentation By Type, Segmentation By Indication, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

24. Italy Small Interfering Ribonucleic Acid (RNA) Market

• 24.1. Italy Small Interfering Ribonucleic Acid (RNA) Market, Segmentation By Type, Segmentation By Indication, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

25. Spain Small Interfering Ribonucleic Acid (RNA) Market

• 25.1. Spain Small Interfering Ribonucleic Acid (RNA) Market, Segmentation By Type, Segmentation By Indication, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

26. Eastern Europe Small Interfering Ribonucleic Acid (RNA) Market

• 26.1. Eastern Europe Small Interfering Ribonucleic Acid (RNA) Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 26.2. Eastern Europe Small Interfering Ribonucleic Acid (RNA) Market, Segmentation By Type, Segmentation By Indication, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

27. Russia Small Interfering Ribonucleic Acid (RNA) Market

• 27.1. Russia Small Interfering Ribonucleic Acid (RNA) Market, Segmentation By Type, Segmentation By Indication, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

28. North America Small Interfering Ribonucleic Acid (RNA) Market

• 28.1. North America Small Interfering Ribonucleic Acid (RNA) Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 28.2. North America Small Interfering Ribonucleic Acid (RNA) Market, Segmentation By Type, Segmentation By Indication, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

29. USA Small Interfering Ribonucleic Acid (RNA) Market

• 29.1. USA Small Interfering Ribonucleic Acid (RNA) Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 29.2. USA Small Interfering Ribonucleic Acid (RNA) Market, Segmentation By Type, Segmentation By Indication, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

30. Canada Small Interfering Ribonucleic Acid (RNA) Market

• 30.1. Canada Small Interfering Ribonucleic Acid (RNA) Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 30.2. Canada Small Interfering Ribonucleic Acid (RNA) Market, Segmentation By Type, Segmentation By Indication, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

31. South America Small Interfering Ribonucleic Acid (RNA) Market

• 31.1. South America Small Interfering Ribonucleic Acid (RNA) Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 31.2. South America Small Interfering Ribonucleic Acid (RNA) Market, Segmentation By Type, Segmentation By Indication, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

32. Brazil Small Interfering Ribonucleic Acid (RNA) Market

• 32.1. Brazil Small Interfering Ribonucleic Acid (RNA) Market, Segmentation By Type, Segmentation By Indication, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

33. Middle East Small Interfering Ribonucleic Acid (RNA) Market

• 33.1. Middle East Small Interfering Ribonucleic Acid (RNA) Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 33.2. Middle East Small Interfering Ribonucleic Acid (RNA) Market, Segmentation By Type, Segmentation By Indication, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

34. Africa Small Interfering Ribonucleic Acid (RNA) Market

• 34.1. Africa Small Interfering Ribonucleic Acid (RNA) Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 34.2. Africa Small Interfering Ribonucleic Acid (RNA) Market, Segmentation By Type, Segmentation By Indication, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

35. Small Interfering Ribonucleic Acid (RNA) Market Regulatory and Investment Landscape

36. Small Interfering Ribonucleic Acid (RNA) Market Competitive Landscape And Company Profiles

• 36.1. Small Interfering Ribonucleic Acid (RNA) Market Competitive Landscape And Market Share 2024
  • 36.1.1. Top 10 Companies (Ranked by revenue/share)
• 36.2. Small Interfering Ribonucleic Acid (RNA) Market - Company Scoring Matrix
  • 36.2.1. Market Revenues
  • 36.2.2. Product Innovation Score
  • 36.2.3. Brand Recognition
• 36.3. Small Interfering Ribonucleic Acid (RNA) Market Company Profiles
  • 36.3.1. Novartis AG Overview, Products and Services, Strategy and Financial Analysis
  • 36.3.2. Thermo Fisher Scientific Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 36.3.3. GlaxoSmithKline plc Overview, Products and Services, Strategy and Financial Analysis
  • 36.3.4. Sanofi S.A. Overview, Products and Services, Strategy and Financial Analysis
  • 36.3.5. Sarepta Therapeutics Inc. Overview, Products and Services, Strategy and Financial Analysis

37. Small Interfering Ribonucleic Acid (RNA) Market Other Major And Innovative Companies

• Alnylam Pharmaceuticals Inc., Ionis Pharmaceuticals Inc., Wave Life Sciences Ltd., Silence Therapeutics plc, Arrowhead Pharmaceuticals Inc., Quark Pharmaceuticals Inc., Arbutus Biopharma Corporation, Evox Therapeutics Ltd., Phio Pharmaceuticals Inc., Genecon Biotechnologies Co. Ltd., Olix Pharmaceuticals Inc., Benitec Biopharma Ltd., Bio-Path Holdings Inc., Calando Pharmaceuticals Inc., Sirnaomics Ltd.

38. Global Small Interfering Ribonucleic Acid (RNA) Market Competitive Benchmarking And Dashboard

39. Key Mergers And Acquisitions In The Small Interfering Ribonucleic Acid (RNA) Market

40. Small Interfering Ribonucleic Acid (RNA) Market High Potential Countries, Segments and Strategies

• 40.1 Small Interfering Ribonucleic Acid (RNA) Market In 2030 - Countries Offering Most New Opportunities
• 40.2 Small Interfering Ribonucleic Acid (RNA) Market In 2030 - Segments Offering Most New Opportunities
• 40.3 Small Interfering Ribonucleic Acid (RNA) Market In 2030 - Growth Strategies
  • 40.3.1 Market Trend Based Strategies
  • 40.3.2 Competitor Strategies

41. Appendix

• 41.1. Abbreviations
• 41.2. Currencies
• 41.3. Historic And Forecast Inflation Rates
• 41.4. Research Inquiries
• 41.5. The Business Research Company
• 41.6. Copyright And Disclaimer